Paweł Miękus

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed et al. · The Lancet · 2018 · 1.7K citations · Full text

Diabetes Management, Cardiovascular Disease, Diabetes +6

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction

Sunil V. Rao, Bodo Kirsch, Deepak L. Bhatt et al. · Circulation · 2022 · 142 citations · Full text

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 94 citations · Full text

Obesity, Metabolic Syndrome, Camellia-timi 61 +9

Management and 1‐Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD‐AF Registry

Shinya Goto, Pantep Angchaisuksiri, Jean‐Pierre Bassand et al. · Journal of the American Heart Association · 2019 · 54 citations · Full text

Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy

Kieran F. Docherty, Pardeep S. Jhund, Olof Bengtsson et al. · Diabetes Care · 2020 · 42 citations · Full text